Oxaliplatin (OX) after irinotecan (IRI): antitumour activity and clinical benefit of 3rd and higher line chemotherapy with ox for patients (pts) with metastatic colorectal cancer (MCC) after failure of IRI
A. Kretzschmar, J. Metzger, P.C. Thuss-Patience, C.C. Kaufmann, M. Wilhelm, H. Kröning, H. Schumacher, P. ReichardtVolume:
35
Year:
1999
Language:
english
DOI:
10.1016/s0959-8049(99)80696-0
File:
PDF, 116 KB
english, 1999